Analyst Ratings For Iovance Biotherapeutics (NASDAQ:IOVA)
Today, Chardan Capital initiated coverage on Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy.
Some recent analyst ratings include
- 1/22/2018-Chardan Capital initiated coverage with a Buy rating.
- 12/13/2017-B. Riley Reiterated Rating of Buy.
- 10/29/2017-Jefferies Group Reiterated Rating of Buy.
- 10/25/2017-FBR & Co Reiterated Rating of Buy.
- 8/16/2017-Cowen Reiterated Rating of Buy.
Recent Insider Trading Activity For Iovance Biotherapeutics (NASDAQ:IOVA)
Iovance Biotherapeutics (NASDAQ:IOVA) has insider ownership of 13.20% and institutional ownership of 75.92%.
- On 8/25/2016 Sanford Hillsberg, Director, sold 54,000 with an average share price of $8.95 per share and the total transaction amounting to $483,300.00.
- On 8/22/2016 Sanford Hillsberg, Director, sold 54,000 with an average share price of $9.11 per share and the total transaction amounting to $491,940.00.
- On 9/8/2015 Sanford Hillsberg, Director, sold 32,500 with an average share price of $6.99 per share and the total transaction amounting to $227,175.00.
- On 5/6/2015 Sanford Hillsberg, Director, sold 50,000 with an average share price of $10.00 per share and the total transaction amounting to $500,000.00.
- On 11/5/2013 Manish Singh, CEO, bought 125,000 with an average share price of $2.00 per share and the total transaction amounting to $250,000.00.
Recent Trading Activity for Iovance Biotherapeutics (NASDAQ:IOVA)
Shares of Iovance Biotherapeutics closed the previous trading session at 11.90 up +1.20 11.21% with 11.550999641418457 shares trading hands.
